At 100 days, 6 months and 12 months, approximately 6 to 8% of patients expressed regret; a total of 15% expressed regret at any time. At 100 days, 6 and 12 months, between 6 and 8% of patients expressed regret; a total of 15% expressed regret at some point. Regret was associated with a decrease in FACT-BMT at 6 and 12 months (p. 30 out of 100 patients are rejected)).
The risk of rejection is highest in the first 6 months after the transplant. After this time, the body's immune system is less likely to recognize that the liver comes from someone else. People who receive a kidney transplant may be exposed to many situations of physical and psychological stress, in addition to the need to face new anxieties to cope with them, such as following a complex medical regimen and being afraid of rejection in the post-transplant period. Transplant Evidence Center, Nuffield Department of Surgical Sciences, Oxford University Transplant Center, Churchill Hospital, Old Road, Oxford OX3 7LN, UK.
In light of the findings that kidney transplant recipients experience depression, anxiety, and stress during the post-transplant period, it is recommended to support kidney transplant recipients after transplantation and implement interventions aimed at reducing their levels of depression, anxiety, and stress. In the present study, the authors investigated whether patients expressed regret after undergoing HCT and the relationship between clinical outcomes and quality of life. Regret for decision-making is a negative emotion that involves distress or remorse following a health care decision and has been associated with lower satisfaction with medical decision-making and a lower quality of life. Supporting recipients after a kidney transplant is recommended, and interventions aimed at reducing depression, anxiety and stress are needed.
While this study has a limited sample size and the use of a single element to operationalize regret, this research provides the first longitudinal evaluation of regret for the decision among patients after HCT and may provide an initial reference point for regret for an allogeneic transplant. Box charts were used to show the relationship between FACT-BMT scores and regret at each time, and T-tests to evaluate differences in average scores. Similar analyses were performed to investigate the relationship between post-HCT regret and AGVHD, cGVHD, and relapse. However, it is known that the psychosocial problems experienced by kidney transplant recipients after transplantation can endanger quality of life and increase rates of mortality and morbidity.
Future work should explore regret in other patient groups and use qualitative methods to report best practices to reduce regret. Uncertainty about the future after transplantation, fear of the unknown, physiological and psychological side effects of long-term pharmacotherapy, changes in social life, depression and stress can cause anxiety in recipients. We investigated whether patients expressed regret after HCT and the relationship between clinical outcomes and quality of life. Relapse, cGVHD and AGVHD are clinical data reported by transplant centers and evaluated 100 days after TCH, 6 and 12 months after TCH.
We used data from the Center for International Blood and Bone Marrow Transplant Research from 184 adults who completed the functional evaluation of cancer therapy: bone marrow transplant (FACT-BMT) before ALOHCT and at day 100. Box charts with the scores of the functional evaluation of cancer treatment: bone marrow transplant (FACT-BMT) at the beginning of the study, at 100 days, 6 and 12 months, stratified by patients who expressed regret and by patients who didn't.
